Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD) is anticipated to post its Q4 2025 results after the market closes on Tuesday, February 10th. Analysts expect the company to announce earnings of $1.87 per share and revenue of $7.68 billion for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 4:30 PM ET.

Gilead Sciences Trading Up 0.7%

GILD stock opened at $142.89 on Tuesday. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $143.80. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average is $125.71 and its 200-day moving average is $119.97. The firm has a market cap of $177.28 billion, a P/E ratio of 22.15, a P/E/G ratio of 0.74 and a beta of 0.36.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Argus boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Scotiabank assumed coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target on the stock. Morgan Stanley cut their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Finally, Wolfe Research raised their target price on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Insider Buying and Selling at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares in the company, valued at $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 257,397 shares of company stock valued at $33,385,512 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. Binnacle Investments Inc raised its position in shares of Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 83 shares during the last quarter. 44 Wealth Management LLC grew its stake in shares of Gilead Sciences by 3.7% during the second quarter. 44 Wealth Management LLC now owns 2,923 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 105 shares during the period. CYBER HORNET ETFs LLC increased its holdings in Gilead Sciences by 3.8% in the third quarter. CYBER HORNET ETFs LLC now owns 3,351 shares of the biopharmaceutical company’s stock valued at $372,000 after purchasing an additional 122 shares during the last quarter. Gould Capital LLC lifted its stake in Gilead Sciences by 1.0% in the third quarter. Gould Capital LLC now owns 13,458 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 131 shares during the period. Finally, Keebeck Wealth Management boosted its holdings in Gilead Sciences by 6.7% during the third quarter. Keebeck Wealth Management now owns 3,138 shares of the biopharmaceutical company’s stock worth $348,000 after buying an additional 196 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.